RPL18A

Across TCGA pan-cancer cohorts, RPL18A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RPL18A data layer compared with 19 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RPL18A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL18A expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where RPL18A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.745	0.302	.002	35	view →
CCRCC	OS	Median	All	0.629	1.000	.002	15	view →
UCEC	DFS	Median	II,III,IV	0.883	0.533	.032	10	view →
GBM	DFS	Quartile	All	0.206	0.440	.015	6	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.906	.018	6	view →
LSCC	OS	Median	All	0.858	0.712	.034	2	view →
PDAC	OS	Quartile	II,III,IV	0.624	0.317	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RPL18A–LUAD (DFS)

Open the LUAD breakdown →